JCP
BLUE

Jabre Capital Partners’s bluebird bio BLUE Stock Holding History

Jabre Capital Partners’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-772
Closed -$1.05M – 93
2017
Q2 		$1.05M Buy
+772
New +$932K 0.09% 95

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Jabre Capital Partners's BLUE Position: Q3 2017 in Review

Jabre Capital Partners sold out of bluebird bio (BLUE) in Q3 2017, closing a stake of 772 shares — an estimated $1.05M sold.

Jabre Capital Partners first reported a position in BLUE in Q2 2017 and held it in 1 quarter. The position peaked at $1.05M in Q2 2017. 243 funds tracked by Wall St. Rank hold BLUE as of Q3 2017.

  • Jabre Capital Partners reported no remaining bluebird bio position as of Q3 2017 after selling out during the quarter.
  • Jabre Capital Partners sold 772 bluebird bio shares in Q3 2017, an estimated $1.05M.
  • Jabre Capital Partners first reported a position in bluebird bio in Q2 2017 and held it in 1 quarter.
  • Jabre Capital Partners's bluebird bio position peaked at $1.05M in Q2 2017.
  • 243 funds tracked by Wall St. Rank held bluebird bio as of Q3 2017.

Based on Jabre Capital Partners's 13F filing for Q3 2017, filed 14 Nov 2017.